.Nature Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a typical follow-up of 11 months, patients with metastatic intestinal tumors who received biomarker-matched therapies based upon distributing tumor DNA profiling presented a more significant clinical benefit than those acquiring incomparable therapy.